Back to News
Latest MHRA Drug Safety Update - January 2019
Posted on 16 Jan 2019
The latest MHRA Drug Safety Update, January 2019
This month article features are:
- tapentadol may increase seizure risk in patients taking other medicines that lower seizure threshold (page 2). Read also about reports of serotonin syndrome when tapentadol is used in combination with serotoninergic antidepressants.
- advice for prescribers of ipilimumab, authorised for advanced melanoma, following post-marketing cases of gastrointestinal cytomegalovirus (CMV) infection or reactivation in patients reported to have corticosteroid-refractory immune-related colitis (page 4). Diagnostic work-up to exclude infectious or other causes should be performed upon presentation with diarrhoea or colitis and in patients who do not respond to steroid treatment for immune-related colitis.
- updates made to the Yellow Card App, which you can use to report suspected adverse drug reactions (ADRs) to the MHRA and be informed of the latest safety alerts, including Drug Safety Updates. The app has new improved features to better capture safety information related to medicine exposure during pregnancy. Download the App today and let us know your thoughts (see page 6).